IMI €115m Call for proposals launch
Enlarge image


IMI €115m Call for proposals launch

18.12.2014 - IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

The Brussels-based Innovative Medicines Initiative (IMI) has launched a 3rd Call for proposals to develop vaccines and medicines for the future. In addition to whooping cough (pertussis), the project’s topics include remote assessment of disease; diabetes; psychiatric disorders; vaccine manufacture and patient involvement in research.

Vaccines do exist for whopping cough, but a resurgence in the number of cases in certain countries is cause for concern. There are currently around 16 million cases and 195,000 deaths from whooping cough worldwide. IMI’s new project will make it possible to refine vaccination schedules to make them more effective and facilitate the development of new and improved vaccines.

‘It is unacceptable that a vaccine-preventable disease like whooping cough remains a leading cause of death for young people around the world,’ said Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation. ‘We are excited to identify and develop more effective vaccines because when kids are healthier, communities and economies thrive.’

IMI’s vaccines project aims to develop and redefine a new approach to testing the quality of vaccines during the production process that will significantly reduce the need for animal testing. Vaccines have also been the focus of IMI's last Call for proposal aimed to address the Ebola crisis

At the same as it launches its 3rd call, IMI will launch its 4th call for proposals with the aim of establishing a platform to coordinate activities relating to speeding up patient access to new medicines. “The IMI is committed to speeding up both medicines development and patient access to new medicines, especially in areas where treatments are lacking. I am confident that the resulting projects will contribute to making a real difference to patients’ lives,” said Irene Norstedt, IMI’s Acting Executive Director.



16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.


11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.


10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.


09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.


05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.


03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.


01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

© 2007-2014 BIOCOM


All Events

Current issue

All issues

Product of the week